KEY FINDINGS: The outbreak is caused by Bundibugyo virus, a distinct Ebola virus species for which no licensed vaccine or specific treatment is currently available. This limits the availability of virus-specific medical countermeasures and reinforces the importance of early diagnosis, supportive clinical care, and rigorous infection prevention and control.
Healthcare facilities should maintain heightened awareness of compatible illness in patients with relevant travel or exposure histories. Prompt identification, appropriate isolation, laboratory testing, contact tracing, and coordinated public health response remain critical to reducing transmission. ECDC continues to monitor the outbreak and provide epidemiological updates and risk assessments.
BACKGROUND: An outbreak of Ebola disease caused by Bundibugyo virus (BDBV) has been ongoing in the Democratic Republic of the Congo (DRC) since May 2026. The outbreak has expanded beyond the DRC, with imported cases reported in Kenya and Nigeria during October. The emergence of cases across multiple countries underscores the importance of early case recognition, cross-border surveillance, infection prevention and control (IPC), and coordinated public health preparedness.
DETAILS: According to the European Centre for Disease Prevention and Control (ECDC), as of 29 October 2026, the DRC had reported 10,274 confirmed cases and 4,992 related deaths, based on data through 28 October. Community transmission continues across eight provinces. Kenya reported nine confirmed cases, including two deaths, as of 26 October. All cases were epidemiologically linked to the initial imported case, with no evidence of wider community transmission reported in the available assessment. The second death was reported on 23 October in a patient who was the third confirmed case in the Kenyan cluster.
Nigeria reported an Ebola case on 20 October in an individual with a travel history to Uganda. The patient was subsequently medically evacuated to Switzerland. As of 29 October, 62 contacts had been identified and were under follow-up. Epidemiological investigations and contact tracing remain ongoing.
The outbreak continues to pose a substantial public health challenge, particularly in the DRC, where sustained community transmission and high mortality have been reported. The expansion into Kenya and Nigeria highlights the potential for international spread through population movement and travel.
In Kenya, the identification of nine cases, including two deaths, within a single epidemiologically linked cluster suggests that contact tracing and isolation have been central to containing transmission. However, the continued occurrence of cases requires sustained monitoring. ECDC emphasizes that the outbreak may be larger than currently reported because of gaps in epidemiological information and incomplete contact follow-up.
Copyright © Skyscape. All rights reserved.
Source: European Centre for Disease Prevention and Control (ECDC). Ebola disease: Multi-country outbreak 2026. ECDC. 2026; Published: October 30, 2026.
KEY FINDINGS: The study changes the interpretation of picobirnaviruses detected in human and animal specimens. Their presence in stool does not necessarily indicate direct infection of the host or zoonotic transmission; the same virus may instead be detected in different animals because they carry the same bacterial species. The findings also have implications for research into the gut microbiome and human disease. Although PBVs have previously been associated with several clinical conditions, this study does not establish a causal role in those diseases. If PBVs are predominantly bacterial viruses, their potential effects on health may involve changes in bacterial populations and microbiome function.
The authors acknowledge that the host range of PBVs remains uncertain and that the findings from PBV-18941 cannot automatically be generalized to every member of the Picobirnaviridae family. Further work is needed to characterize additional PBVs, establish their bacterial hosts and determine whether they influence disease-associated microbial communities.
BACKGROUND: This study challenges the traditional understanding of picobirnaviruses as viruses associated with eukaryotic hosts. It presents evidence that a human gut-associated picobirnavirus belongs to a distinct lineage of RNA bacteriophages—viruses that infect bacteria—positioning the family Picobirnaviridae as a third major clade of RNA bacteriophages.
Picobirnaviruses (PBVs) are double-stranded RNA viruses frequently detected in faecal samples from humans and animals. They have been associated with several conditions, including diarrhoea, enteric graft-versus-host disease, irritable bowel syndrome and type 1 diabetes in pregnant women. However, these associations have not established that PBVs directly infect vertebrate cells or cause disease. Despite their widespread detection, PBVs had remained difficult to characterize because no reliable culture system or animal model was available. Their true biological hosts were therefore uncertain. The possibility that they infect microorganisms living in the gut, rather than human or animal cells, had been proposed but not experimentally established.
DETAILS: Researchers investigated two previously unreported PBVs identified in human stool samples collected in the United Kingdom. The viruses, designated PBV-18941 and PBV-19022, were first propagated in germ-free mice following faecal microbiota transplantation. Viral RNA increased substantially in at least one mouse for each virus: PBV-18941 increased 10⁷-fold and PBV-19022 increased 10⁶-fold. Both persisted through day 23. Further experiments demonstrated that PBV-19022 could be serially propagated in mice. Neomycin treatment eventually eliminated the virus, suggesting a possible relationship with an antibiotic-sensitive bacterial host. The investigators subsequently established an anaerobic in vitro culture system using the gut microbial community from PBV-positive mouse stool. PBV-18941, but not PBV-19022, persisted through 20 passages. Its growth was eliminated by neomycin, vancomycin and metronidazole, providing further evidence that bacterial growth was necessary for its propagation.
RNA fluorescence in situ hybridization demonstrated that both genomic segments of PBV-18941 were present inside bacterial cells. Fluorescence-activated cell sorting and sequencing identified a previously undescribed Anaerotignum species, proposed as ‘Candidatus Anaerotignum faecalis', as the bacterial host. PBV RNA was detected in this organism but not in the other prominent bacterial species identified in the sorted community. The identified bacterium represented approximately 0.3% of the total bacterial community, and approximately 10% of its cells were infected by PBV-18941. The researchers were unable to isolate ‘Ca. A. faecalis' as a pure culture, which remains an important limitation.
The findings provide direct experimental evidence that PBV-18941 infects bacteria rather than vertebrate cells, establishing it as an RNA bacteriophage. The study therefore identifies Picobirnaviridae as the third recognized clade of RNA bacteriophages, alongside leviviruses and cystoviruses. Importantly, PBV-18941 infects a Gram-positive bacterium, expanding the known host range of characterized RNA phages, which had previously been associated primarily with Gram-negative bacteria.
Copyright © Skyscape. All rights reserved.
Source: Gan, T., Rosen, A. L., Wang, L., et al. A human gut-associated picobirnavirus establishes the Picobirnaviridae as the third clade of RNA bacteriophages. Nature Microbiology. Published: October 29, 2026. DOI: 10.1038/s41564-026-02523-z.
PUBLIC HEALTH ALERT
Updated October 17, 2026 | Source: US Centers for Disease Control and Prevention (CDC)
[Posted 19/Oct/2026]
AUDIENCE: Infectious Disease, Internal Medicine
Key Surveillance Findings: According to the CDC, 4,410 confirmed measles cases were reported in the United States during 2026 as of October 15. Cases were reported across 47 jurisdictions, with 18 cases involving international visitors. The CDC recorded 42 new outbreaks during the year, and 96% of confirmed cases (4,228 of 4,410) were associated with outbreaks. This total includes cases linked to outbreaks that began in both 2025 and 2026.
The contrast with earlier years is marked. The United States reported 285 cases in 2024 and 2,289 in 2025. The current 2026 total reflects a significant increase in transmission and underscores the vulnerability of communities with inadequate immunization coverage.
Backround: The United States is experiencing a substantial resurgence of measles, with 4,410 confirmed cases reported as of October 15, 2026. The total has already exceeded the 2,289 cases recorded throughout 2025 by approximately 93%, highlighting the ongoing challenge of controlling a highly contagious, vaccine-preventable infection.
Declining Vaccination Coverage Raises Concern: Measles was declared eliminated in the United States in 2000, meaning sustained endemic transmission had been interrupted. However, imported infections can trigger outbreaks when the virus reaches susceptible populations.
National measles, mumps, and rubella (MMR) vaccination coverage among kindergarteners declined from 95.2% during the 2019-2020 school year to 92.4% in 2025-2026. The CDC estimates that approximately 280,000 kindergarteners were at risk during the 2025-2026 school year. Because measles spreads exceptionally efficiently, clusters of unvaccinated individuals can sustain transmission even in areas where overall vaccination coverage appears relatively high.
Two doses of MMR vaccine are approximately 97% effective against measles, compared with 93% effectiveness after one dose. Maintaining high coverage and identifying susceptible individuals remain central to preventing further spread.
Clinical and Public Health Implications
Clinicians should remain alert to possible measles in patients with compatible symptoms, particularly when there is a history of travel, known exposure, or residence in an affected community. Measles can cause serious complications, especially in infants and young children. Suspected cases require prompt infection-control precautions and coordination with public health authorities; patients should not be directed into routine waiting areas where others may be exposed.
Healthcare professionals should review patients’ immunization histories, recommend vaccination in accordance with current guidance, and reinforce the importance of protection before international travel. Public health teams should continue surveillance, contact tracing, and targeted vaccination efforts in communities with low coverage.
Key Takeaway
The rise to more than 4,400 confirmed cases in 2026 demonstrates that measles elimination does not eliminate the risk of renewed outbreaks. Sustained vaccination coverage, rapid recognition of suspected cases, and coordinated public health action are essential to limit transmission and protect vulnerable populations.
Data note: CDC surveillance figures are provisional and include confirmed cases reported by jurisdictions as of noon on Thursday, October 15, 2026. Counts may change as additional cases are confirmed. An outbreak is defined by the CDC as three or more related cases.
Copyright © Skyscape. All rights reserved.
Source: US Centers for Disease Control and Prevention. Measles Cases and Outbreaks. Updated October 16, 2026. CDC.
KEY FINDINGS: Aztreonam/avibactam retained substantial in vitro activity against Enterobacterales resistant to other advanced beta-lactam/beta-lactamase inhibitor combinations, including MBL-producing organisms. The findings are particularly relevant as NDM and other MBLs increasingly complicate the treatment of CRE infections. These results support the potential role of aztreonam/avibactam as a treatment option for selected infections caused by resistant Gram-negative bacteria. However, laboratory susceptibility findings do not establish clinical effectiveness in individual patients. Treatment decisions should incorporate susceptibility testing, infection site, patient factors, and applicable clinical guidance. Continued surveillance is also necessary to monitor emerging resistance.
BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) are an increasing clinical concern because resistance to newer antibiotics, including ceftazidime/avibactam and meropenem/vaborbactam, limits treatment options for serious infections. Metallo-beta-lactamase (MBL)-producing organisms pose a particular challenge because these enzymes can inactivate many beta-lactam antibiotics. Aztreonam/avibactam combines aztreonam's stability against MBL-mediated hydrolysis with avibactam's inhibition of several other beta-lactamases. This study assessed its in vitro activity against resistant Enterobacterales collected from US medical centers.
DETAILS: Investigators analyzed 80,927 Enterobacterales isolates collected from 103 US medical centers between 2016 and 2024, with one isolate per patient. Antimicrobial susceptibility was evaluated using broth microdilution. The analysis focused on isolates that were not susceptible to ceftazidime/avibactam, meropenem/vaborbactam, or both, as well as carbapenem-resistant and MBL-producing isolates. Whole-genome sequencing was used to identify carbapenemase genes in resistant isolates. Among the collected isolates, 194 (0.24%) were not susceptible to ceftazidime/avibactam or meropenem/vaborbactam, 115 (0.14%) were not susceptible to both combinations, and 832 (1.0%) were carbapenem resistant.
Aztreonam/avibactam demonstrated activity against 91.9% of ceftazidime/avibactam-nonsusceptible isolates and 94.0% of meropenem/vaborbactam-nonsusceptible isolates. Activity was observed against 98.1% of CRE isolates and 98.4% of MBL-producing isolates. Cefiderocol was active against 78.8% of ceftazidime/avibactam-nonsusceptible isolates, 83.2% of meropenem/vaborbactam-nonsusceptible isolates, 94.7% of CRE isolates, and 82.1% of MBL producers. Genetic analysis identified carbapenemase genes in 159 (82.0%) of isolates nonsusceptible to ceftazidime/avibactam or meropenem/vaborbactam and in 683 (80.1%) of CRE isolates. New Delhi metallo-beta-lactamase (NDM) was the most common carbapenemase among the resistant isolates, identified in 114 (58.8%). Notably, MBL-producing organisms accounted for 36.1% (73/202) of CRE isolates collected during 2023–2024, highlighting the importance of continued resistance surveillance.
Copyright © Skyscape. All rights reserved.
Source: Sader, H. S., Papp-Wallace, K. M., Kimbrough, J. H., et al. Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024). Journal of Antimicrobial Chemotherapy. 2026; 81(10). Published: October, 2026. DOI: 10.1093/jac/dkag308.
KEY FINDINGS: In this large US observational analysis, publication of randomized trial evidence in 2016 was followed by a substantial increase in adjunctive azithromycin use during unscheduled cesarean delivery and a relative reduction in postpartum infections. The study provides evidence that clinical trial findings were subsequently incorporated into routine practice beyond the original trial setting. Because this was an observational difference-in-differences analysis rather than a new randomized trial, the findings demonstrate an association between adoption of the intervention and changes in infection rates rather than establishing causality.
BACKGROUND: Unscheduled cesarean delivery is associated with a higher risk of postpartum infection. A 2016 clinical trial showed that adding azithromycin to standard antibiotic prophylaxis could reduce postoperative infections in patients undergoing unscheduled cesarean delivery. This study evaluated whether use of adjunctive azithromycin increased after publication of that trial and whether postpartum infection rates subsequently changed in routine US practice.
DETAILS: Investigators conducted a difference-in-differences analysis using Epic Cosmos data from 2013 through 2024. The analysis included pregnant individuals who received prenatal care, experienced labor, and delivered a live singleton infant at 24 to 43 weeks' gestation. Cesarean deliveries served as the treatment group and vaginal deliveries as the comparison group, allowing changes occurring after publication of the 2016 trial to be assessed relative to trends in vaginal births.
The study included 1,663,441 deliveries, comprising 202,234 cesarean births and 1,461,207 vaginal births. The primary outcomes were perioperative azithromycin administration and postpartum infection occurring within 6 weeks of delivery. The investigators compared births from January 1, 2013, through September 28, 2016, with those occurring from January 1, 2017, through December 31, 2024.
Before publication of the 2016 trial, azithromycin was administered during 2.2% of cesarean births compared with 0.01% of vaginal births. During 2017-2024, use increased to 39.6% of cesarean births and 0.04% of vaginal births. The adjusted difference-in-differences estimate for cesarean births was 37.6 percentage points (95% CI, 33.1 to 42.2). Postpartum infection after cesarean delivery declined from 9.2% during the pre-2016 period to 8.0% during 2017-2024. Among vaginal births, infection rates changed from 2.0% to 2.7%, producing an adjusted difference-in-differences estimate of -2.0 percentage points (95% CI, -2.6 to -1.4) for cesarean births. The findings therefore showed that, following publication of the randomized trial, adjunctive azithromycin use increased substantially among patients undergoing unscheduled cesarean delivery while postpartum infection rates decreased relative to the comparison group.
Copyright © Skyscape. All rights reserved.
Source: Freret, T. S., Litman, E., Wen, T., et al. Adoption of Adjunctive Azithromycin for Unscheduled Cesarean Delivery and Postpartum Infections. JAMA. 2026; Published: September 14, 2026. DOI: 10.1001/jama.2026.15010.
KEY FINDINGS: The analysis suggests that excluding long-term illness, mortality, and healthcare costs after TB treatment can substantially underestimate the health value of TB prevention. In the modeled Canadian immigrant population, incorporating these consequences more than doubled the estimated QALY benefit of postarrival TB infection screening and preventive treatment and reduced the estimated cost per QALY by more than half. However, the findings depend on assumptions about the long-term effects of TB, and the investigators noted that some underlying associations may include residual confounding and that post-TB illness estimates are less certain.
BACKGROUND: Tuberculosis prevention strategies are commonly evaluated by considering acute TB disease and death, while longer-term consequences after successful treatment may be overlooked. These consequences can include persistent illness, increased mortality, and additional healthcare utilization. This study assessed how incorporating these longer-term effects would change estimates of the health benefits and cost-effectiveness of postarrival TB infection screening and preventive treatment among people newly immigrating to Canada.
DETAILS: The investigators developed a Markov microsimulation model representing a hypothetical cohort of 400,000 people immigrating permanently to Canada in 2025. The analysis compared the existing postarrival TB infection screening level of 0.5% with a modeled screening strategy reaching 68% of eligible new immigrants. The intervention targeted new permanent residents from countries with annual TB incidence >50/100,000 persons; individuals testing positive for TB infection were assumed to receive 4 months of daily rifampin as preventive treatment. Outcomes were projected over 25 years and included TB episodes, TB deaths, quality-adjusted life-years (QALYs), and TB-related healthcare costs. The model incorporated three post-TB consequences: increased mortality after TB treatment, persistent illness or disability, and excess healthcare costs. A total of 2,000 probabilistic simulations were performed to account for uncertainty in model parameters.
When only acute TB consequences were considered under the current screening scenario, the model projected 927 (95% UR 764-1,123) TB cases, 30 (95% UR 24-36) TB deaths, and 312 (95% UR 241-386) QALYs lost over 25 years. Adding post-TB death increased estimated QALYs lost by 1.6-fold, while including post-TB illness increased them by 1.5-fold. When all three long-term consequences were incorporated, TB was projected to account for 657 (95% UR 479-876) QALYs lost, a 2.1-fold increase compared with considering acute consequences alone.
The expanded screening and preventive-treatment strategy produced 2.4-fold greater estimated QALY gains (95% UR 1.6-4.4-fold) and 2.2-fold more TB deaths averted (95% UR 1.6-3.0-fold) when all post-TB consequences were included. The estimated incremental cost-effectiveness ratio decreased from $235,088 to $100,742 CAD per QALY gained. In the model incorporating all post-TB consequences, 53% of simulations fell below a willingness-to-pay threshold of $100,000 per QALY, compared with 8% when only acute TB consequences were considered.
Copyright © Skyscape. All rights reserved.
Source: Ainiwaer, A., Uppal, A., Schwartzman, K., et al. Posttuberculosis Consequences on Tuberculosis Prevention Effectiveness and Cost-effectiveness among New Immigrants, Canada. Emerging Infectious Diseases. 2026; 32(9): 1421-1429. Published: September, 2026. DOI: 10.3201/eid3209.260473.
Specialty: